**Core tip:** In the last decades, surgical gastrojejunostomy and enteral stenting have represented the main palliative strategies for patient with malignant gastric outlet obstruction. Although they showed good clinical efficacy, these approaches suffer from limits secondary to the high procedure-related risks and longer hospital stay (surgery) or the need subsequent re-interventions due to stent dysfunction (endoscopic stenting). The recently proposed endoscopic ultrasonography-guided gastroenterostomy may include both advantages of a minimally invasive endoscopic procedure and the long-lasting benefits of the gastrojejunostomy. However, such procedure is not standardized and prospective comparative studies are needed to define the best strategy for these patients.

INTRODUCTION
============

Malignancies of the pancreas, biliary tract and gastro-duodenum are often diagnosed in advanced stages, in many cases are not amenable of curative surgical treatment and thus may require prolonged radio-chemotherapy regimens or palliative care. In this setting, malignant gastric outlet obstruction (MGOO) is defined as the mechanical obstruction of the pylorus or the duodenum secondary to compression/infiltration from advanced loco-regional malignancies that make difficult or even impossible the oral feeding (Figure [1](#F1){ref-type="fig"}). Patients with MGOO typically present with nausea and vomiting, which could associate with abdominal pain, weight loss, malnutrition and dehydration secondary to poor oral intake\[[@B1]\]. The most frequent cause of MGOO in the Western countries is pancreatic adenocarcinoma, which lead to obstructive symptoms in about 15%--20% of patients during the disease course, while gastric adenocarcinoma is the most common cause in Asiatic population\[[@B2]-[@B7]\]. Less common causes are duodenal or ampullary neoplasms, biliary cancers, lymphomas or adenopathies from other malignancies\[[@B1]\]. Effective treatment of MGOO is of paramount importance either for patients who have to face radio-chemotherapy regimens, as for those at late stage of disease who only require supportive care aimed at improving quality of life. For many decades MGOO has been managed with open surgical gastrojejunostomy, during which also biliary bypass was performed in case of concomitant biliary obstruction\[[@B8]-[@B10]\]. However, most patients with MGOO often present with advanced disease and are not optimal candidates for open surgery. Due to the high surgical risk and the short life expectation (*i.e*. 3-4 mo) that characterize the majority of these patients, less invasive approaches have been developed and proposed over time, aimed at providing fast and effective relieve of symptoms and return to an adequate oral feeding with the highest safety, the shortest hospitalization time and the lowest costs. Such an ambitious goal has been pursued with the use of enteral stents, with the development of less invasive surgical techniques (*i.e*. laparoscopic gastrojejunostomy) and, more recently, with the progress of interventional endoscopic ultrasonography (EUS), and the development of EUS-guided gastroenterostomy techniques (EUS-GE) (Figure [2](#F2){ref-type="fig"}). A consistent body of literature exists about the outcome and safety of such interventions in the setting of MGOO. Nevertheless, few randomized clinical trials have been conducted to compare these different approaches, and so there is still uncertainty about the best strategy to choose.

![Computed tomography scan appearance of malignant duodenal stricture with gastric distension due to pancreatic cancer.](WJG-26-1847-g001){#F1}

![Graphic representation of the main approaches applied to manage malignant gastric outlet obstruction. A: Surgical gastrojejunostomy; B: Endoscopic enteral stenting with self-expanding metal stents; C: Endoscopic ultrasound-guided gastroenterostomy.](WJG-26-1847-g002){#F2}

In this review, we aimed to summarize the available evidence on the most common palliative strategies for MGOO, focusing on the strength and weakness of each approaches and discussing possible unanswered questions that should be addressed in future studies.

ROLE OF ENTERAL STENTS
======================

From the late 90's endoscopic enteral stenting has been proposed as a minimal invasive treatment for MGOO, using the experience gained from the use of expanding and self-expanding metal stents (SEMS) in the setting of malignant esophageal strictures\[[@B11]-[@B13]\]. Generally, a wire is passed through the gastro-duodenal stricture under endoscopic and fluoroscopic assistance, and subsequently the metal stent is passed over the wire and released across the stenosis. According to specific endoscopist's preference, a soft angled wire can be used first to pass the stricture, and then exchanged with a stiffer one using a catheter. Moreover, passing a catheter over the wire allow to inject contrast to define the anatomy (*i.e*. length, angulation) of the stenosis, in order to optimize the size of the stent. Over the time, different techniques to deploy enteral stents across gastro-duodenal strictures have been described. After positioning a wire across the stricture, interventional radiologists could deploy the stent with an over-the-wire technique exclusively under fluoroscopic assistance\[[@B14],[@B15]\]. Alternatively, the stent can be deployed under endoscopic and fluoroscopic view; using the over-the-wire technique the endoscope is positioned parallel to the wire, while, with the through-the scope technique, the stent is inserted over the wire into the working channel of the endoscope\[[@B16]-[@B19]\]. Currently, the endoscopic deployment using through-the scope stents is the most used technique, and requires therapeutic endoscopes with a large working channel (*i.e*., ≥ 3.7 mm). Most cases are managed with therapeutic gastroscopes, but cases of dilated stomachs or strictures in the distal duodenum could be better managed with a colonoscope or a duodenoscope\[[@B20],[@B21]\]. Moreover, tight and angulated stenosis could be negotiated in an easier way using a sphincterotome, with the additional advantage of the elevator of the duodenoscope. The choice of the stent largely depend on the stricture anatomy and the endoscopist's preference. Over time, several different types of enteral metal stent have been designed, which differed in type of metal alloy, length, diameter and radial expansive force after deployment\[[@B1],[@B18],[@B22]-[@B25]\] (Figure [3](#F3){ref-type="fig"}). Currently, available enteral SEMS are made of nitinol, an alloy of nickel and titanium, which confers high flexibility useful for sharply angulated strictures, even if with a weaker expansive radial force compared to other metal stents\[[@B26]\]. Several studies on enteral SEMS for MGOO have shown a high rate of technical success (defined as the successful deployment of the stent across the stricture), which is usually above 90%, and a good rate of clinical success, which ranges from 63% to 97%\[[@B27]\]. Clinical success is generally defined as the relief of obstructive symptoms and the improvement of food oral intake. Adler and colleagues developed a clinical score aimed at providing an objective measure of the oral intake before and after the treatment for MGOO\[[@B19]\]. The Gastric Outlet Obstruction Scoring System (GOOSS) assigns a score of 0 in case of no oral intake, 1 for only liquids, 2 for soft solids and 3 for low-residues or full diet, and currently is the most used score to quantify the clinical improvement after treatment for MGOO\[[@B19]\]. However, high heterogeneity exists among published studies on the definition of this outcome, and a systematic review from Larssen et al\[[@B28]\] highlighted that only 40% of studies used a graded scoring system to evaluate the effect of stenting on MGOO. A systematic review of 32 studies (606 patients) reported a technical success rate of 97% and a clinical success rate of 89% (87% in the intention-to-treat analysis), with a mean GOOSS that rose from 0.4 to 2.4 after treatment, and a resolution of symptoms after a mean period of 4 d\[[@B29]\]. Similarly, a systematic review of 1046 patients treated with duodenal SEMS published in 2007 reported a technical success and clinical success rate of 96% and 89% respectively, with a significant improvement of GOOSS\[[@B30]\]. A recent systematic review from van Halsema and colleagues included 19 prospective studies from 2009 to 2016 and analyzed outcomes of more than 1200 patients with MGOO treated with SEMS. The overall pooled technical success rate was 97.3% and the clinical success rate was 85.7%, thus confirming the high efficacy of this technique\[[@B27]\]. Several studies investigated potential predictive factors of clinical failure or stent dysfunction, in order to optimize the outcome of patients with MGOO undergoing stent placement. The presence of carcinomatosis and a poor performance status (Karnofsky performance status \< 50 or Eastern Cooperative Oncology Group status ≥ 3) have been identified as predictors of clinical failure and/or stent dysfunction in several studies\[[@B31]-[@B34]\], while chemotherapy after stent placement has been reported as protective\[[@B35],[@B36]\]. In particular, a retrospective study of 228 patients found that carcinomatosis is a predictive factor of clinical failure only if associated with ascites, while carcinomatosis without ascites did not decrease clinical success rate compared to patients without peritoneal disease\[[@B37]\]. The site of the gastro-duodenal stricture (distal *vs* proximal) and the number of strictures (*i.e*., ≥ 3) are other factors associated with worst outcome in retrospective studies\[[@B31],[@B38]\].

![Final endoscopic appearance of a duodenal uncovered self-expanding metal stent deployed across duodenal stricture, in a patient with gastric outlet obstruction due to pancreatic cancer.](WJG-26-1847-g003){#F3}

Adverse event (AE) rate related to SEMS placement ranges from 0% to 30% depending on the definition adopted in the specific study, and includes minor AEs (non-life threatening) such as nausea, vomiting, mild abdominal pain, or major AE, such as bleeding, perforation, stent migration/displacement, cholangitis\[[@B19],[@B29],[@B30]\] . Delayed AEs are usually related to stent dysfunction, secondary to migration or occlusion by food impaction and/or tumor ingrowth/overgrowth. In the report of 1281 patients that received duodenal SEMS, stent obstruction was reported in 12.6%, stent migration in 4.3%, bleeding in 4.1% (major bleeding in 0.8%) and perforation in 1.2%\[[@B27]\]. A recent retrospective study of 220 patients reported a SEMS-related AE rate of 2%, with 3 fatal cases of perforation and an overall rate of re-intervention of 13% after 4 mo\[[@B39]\]. As stated above, stent may occlude due to food impaction or secondary to tumor progression and ingrowth, that is the tumor growth through the mesh of the stent. Stent occlusion leads to reappearance of gastric obstruction symptoms and often needs endoscopic re-intervention that, although feasible and effective, may affect negatively patients' quality of life and increase costs for the health system, representing one of the main weakness of this approach\[[@B40],[@B41]\]. In order to reduce the risk of stent occlusion, several studies have investigated the possible role of covered SEMS in the setting of MGOO. A systematic review and meta-analysis published in 2014 including 9 studies (849 patients) confirmed that covered SEMS have a lower obstruction rate (RR: 0.42, 95%CI: 0.24-0.73, *P* = 0.002), but at the same time, as expected, have a higher migration risk (RR: 3.48, 95%CI: 2.16-5.62, *P* \< 0.00001)\[[@B42]\]. Interestingly, the Authors reported no significant difference in technical success rate, clinical success rate, post-stenting dysphagia score, stent patency, overall complications and re-intervention rate between covered and uncovered SEMS group. A more recent systematic review including 1624 patients reported similar results, with comparable technical and clinical success rate between covered and uncovered gastroduodenal SEMS\[[@B43]\]. The Authors highlighted a trend toward a lower dysfunction rate in covered SEMS group (RR: 0.63; 95%CI: 0.45-0.88) when performing a sub-analysis of randomized trials. However, it should be noted that the higher risk of migration was confirmed for covered SEMS, together with a higher overall AE rate in this group (RR: 1.75; 95%CI: 1.09-2.83)\[[@B43]\]. Several technical modifications or precautions (*e.g*., stent clipping or suturing, anti-migratory design) have been proposed to overcome the migration risk saving the possible advantages of the lower occlusion rate\[[@B44]-[@B46]\]. Despite these intriguing alternatives, an increased risk of cholangitis and pancreatitis secondary to the compression/occlusion of the ampulla exists with covered SEMS\[[@B22],[@B47]-[@B49]\], and, therefore, uncovered SEMS are still considered the first option in this setting.

Advanced gastro-duodenal or pancreato-biliary malignancies frequently cause biliary obstruction, which is estimated to affect 70%-90% of pancreatic cancer patients during the course of the disease and may appear before, concomitantly or after the onset of MGOO\[[@B1]\]. The presence of MGOO could make the papilla not achievable for standard endoscopic drainage with endoscopic retrograde cholangio-pancreatography (ERCP), in particular for type 1 (proximal to the papilla) or type 2 (at the level of the papilla) duodenal stricture, accordingly to the classification proposed by Mutignani et al\[[@B50]\]. Such cases may be very difficult for therapeutic endoscopists and, therefore, performing biliary drainage with biliary SEMS in patients concomitantly treated for MGOO with risk of impending or future biliary obstruction appears a reasonable strategy, when feasible\[[@B50],[@B51]\]. Although technically challenging, ERCP through an indwelling duodenal stent is feasible and effective, as reported in a recent multicenter retrospective studies on 71 patients, with an overall technical success rate of 85%, which was reduced to 76% in case of duodenal obstruction at the level of the ampulla\[[@B52]\]. The recent progress of interventional EUS, and the possibility to perform EUS-guided biliary drainage (EUS-BD) from the stomach (*i.e*., EUS-guided hepato-gastrostomy) or from the bulb (EUS-guided choledocho-duodenostomy) has radically changed the approach to the patients with concomitant MGOO and biliary obstruction\[[@B53]\]. EUS-BD in patients with MGOO is safe and effective, even when performed in the same session or with an indwelling duodenal stent, and probably could be considered the first-line strategy to achieve biliary drainage in this setting of patients\[[@B54]-[@B56]\].

COMPARISON BETWEEN ENTERAL STENTING AND SURGICAL GASTROJEJUNOSTOMY
==================================================================

Since the introduction of enteral SEMS for palliation of MGOO, a consistent body of literature has been produced to compare this approach to surgical gastrojejunostomy (GJ), aimed at defining which method, and for which patients, had to be preferred in this clinical setting (Figure [4](#F4){ref-type="fig"}). Currently, several retrospective cohort studies, but few randomized controlled studies, are available on this topic, with some conflicting results. A multicenter, prospective, randomized study conducted in The Netherlands between 2006 and 2008 randomized 39 patients with MGOO to duodenal stent placement (21 patients) or surgical GJ (18 patients) (SUSTENT Study)\[[@B57]\]. The Authors found a faster relief of symptoms and improvement of GOOSS in the stent group compared to the surgery group (GOOSS score ≥ 2 after a median period of 5 *vs* 8 d, respectively; *P* \< 0.01), but a more lasting relief in the surgery group, which showed a median period of 72 *vs* 50 d (*P* \< 0.05) with GOOSS score ≥ 2 after the procedure. Major AEs, recurrent obstructive symptoms and re-interventions were more common after stent placement compared with GJ, and this result was mainly dependent on the risk of stent obstruction in the duodenal stent group\[[@B57]\]. The authors concluded that GJ was the treatment of choice in patients with a life expectancy of 2 mo or longer because of the better long-term results, while stent placement was preferable for patients expected to live less than 2 mo due to the better short-term outcomes. Other randomized trials reported favorable results for the duodenal stenting, mainly in terms of shorter hospitalization time compared to surgical GJ\[[@B58],[@B59]\] (Table [1](#T1){ref-type="table"}). However, it should be noted that the cited studies suffer from several limitations, especially for the limited number of patients enrolled and the lack of an adequate statistical power calculation. A recent retrospective study from Jang and colleagues analyzed the outcome of 183 patients who underwent SEMS placement and 127 patients who received surgical GJ over period of 7 years\[[@B60]\]. While the clinical success did not differ significantly between the two groups (79.4% *vs* 80.1%; *P* = 0.83), the mean patency duration was significantly longer in the GJ group compared to the stenting group (169.2 *vs* 96.5 d respectively). Moreover, the GJ group showed longer survival (193.4 *vs* 119.9 d), and the authors concluded that GJ should be considered the primary treatment option for patients with good performance status and reasonable survival expectancy\[[@B60]\]. It should be underlined that the work from Jang et al\[[@B60]\] suffers from possible selection bias, which is the main limitation of many retrospective studies in this field. Indeed, patients who underwent surgery were "healthier" compared to patients selected for endoscopic palliation (Eastern Cooperative Oncology Group score of 1 *vs* 2, respectively; *P* \< 0.001), and this could account for the longer survival in this group. Despite the unquestionable value of the study, the presented results are certainly not conclusive, and high quality evidence is still lacking. Recently, results from 27 studies including 2.354 patients (1.306 treated with SEMS and 1.048 with surgical GJ) have been analyzed in a systematic review with meta-analysis, which concluded that patients with acceptable performance status should be primarily considered for a palliative GJ rather than duodenal stenting\[[@B61]\]. In particular, the study confirmed that mean time to oral intake and length of hospital stay were shorter in the SEMS group compared to surgery group, while the frequency of re-interventions was almost three times higher in the SEMS group (OR: 2.95, CI: 1.70-5.14, *P* \< 0.001), thus remarking that stent dysfunction secondary to migration/dislocation or occlusion/obstruction is the main limitation of the duodenal stenting in MGOO\[[@B61]\]. Surgical techniques other than classic open surgical gastrojejunostomy or laparoscopic gastrojejunostomy have been proposed to overcome the risk of post-operative delayed gastric emptying, such as stomach-partitioning GJ with or without Braun entero-enterostomy, and small retrospective studies have compared such technique with enteral stenting\[[@B62],[@B63]\]. Although intriguing, the study design and the limited number of patients included do not yet allow drawing conclusion about the superiority of this approach over classic surgery or stenting, and larger studies are needed. Comparison of costs between GJ and stenting has produced conflicting results, as the shorter hospitalization documented with enteral stents could be counter-balanced by higher costs for re-interventions\[[@B4],[@B57],[@B61],[@B64],[@B65]\]. Taken together, these data highlight that a correct selection of patients is probably the crucial step to achieve a satisfactory clinical outcome for both strategies.

###### 

Characteristics of the available randomized trials comparing duodenal stenting and surgical gastrojejunostomy for malignant gastric outlet obstruction

  **Ref**.                         **Randomized patients**   **Treated patients**   **Type of stent**                                    **Surgical technique**                         **Main outcome measures**       **Technical success**   **Clinical success**                                                                  **Adverse events**   **Hospital stay (d, median)**   **Reintervention**   **Follow-up**
  -------------------------------- ------------------------- ---------------------- ---------------------------------------------------- ---------------------------------------------- ------------------------------- ----------------------- ------------------------------------------------------------------------------------- -------------------- ------------------------------- -------------------- ---------------------------------------------
  Fiori et al\[[@B58]\], 2004      Stent group: 9            9                      Covered SEMS (Ultraflex, Boston)                     Open GJ                                        Gastric emptying (after 15 d)   9/9 (100%)              9/9 (100%)                                                                            2/9 (22.2%)          3.1                             7/9 (77.7%)          3 mo
  Surgery group: 9                 9                         9/9 (100%)             8/9 (88.9%)                                          2/9 (22.2%)                                    10                              1/9 (11.1%)                                                                                                                                                                             
  Mehta et al\[[@B59]\], 2006      Stent group: 13           12                     Wallstent (Boston)[1](#T1FN1){ref-type="table-fn"}   Laparoscopic GJ                                Safety quality of life          10/12 (83.3%)           Significant improvement in Physical Health score after 1 mo in duodenal stent group   0/10 (0%)            5.2                             NA                   12 mo
  Surgery group: 14                13                        13/13 (100%)           10/13 (76.9%)                                        11.4                                                                                                                                                                                                                                                                   
  Jeurnink et al\[[@B57]\], 2010   Stent group: 21           20                     Wallflex (Boston)                                    Laparoscopic or open GJ                        GOOSS improvement               20/21 (95.2%)           17/21 (80.9%)                                                                         8/21 (38.1%)         7                               2/21 (9.5%)          Median survival: 72 d (GJ) *vs* 50 d (SEMS)
  17/18 (94.4%)                    14/18 (77.7%)             5/21 (23.8%)           15                                                   7/18[2](#T1FN2){ref-type="table-fn"} (38.8%)                                                                                                                                                                                                                           
  Surgery group: 18                17                                                                                                                                                                                                                                                                                                                                                                           

In this study, the stents were positioned under fluoroscopic guidance.

Seven patients experienced 10 adverse events. SEMS: Self-expanding metal stent; GJ: Gastrojejunostomy; GOOSS: Gastric outlet obstruction scoring system.

![Intra-operative image of laparoscopic gastrojejunostomy.](WJG-26-1847-g004){#F4}

ENDOSCOPIC ULTRASONOGRAPHY-GUIDED GASTROENTEROSTOMY
===================================================

The above-cited progress of interventional EUS have enriched the field of therapeutic endoscopy with the possibility to perform trans-luminal procedures, such as trans-gastric or trans-duodenal drainage of peripancreatic fluid collections, gallbladder drainage in patients unfit for surgery or biliary drainage after failed ERCP\[[@B66]-[@B69]\]. In the last years, it has been developed and proposed an innovative technique that allows the creation of a stable gastro-jejunal anastomosis through a EUS-guided procedure, named EUS-guided gastroenterostomy (EUS-GE)\[[@B70],[@B71]\]. With this regard, the field of interventional has enormously benefited from the development of dedicated metal stents for trans-luminal interventions. Indeed, lumen-apposing metal stents (LAMS) are fully covered "dumb-bell"-shaped short stent made up of braided nitinol, specifically designed for interventional EUS procedures, with wide anti-migratory flanges which provide a lumen-to-lumen apposition effect\[[@B68]\]. The stent is pre-loaded in a 10.8 French catheter with a through-the-scope delivery system compatible with therapeutic echoendoscope with a working channel ≥ 3.7 mm. In the EUS-GE procedure, the small bowel is punctured from the stomach at the level of the distal duodenum or in the proximal jejunum (*i.e*. gastroduodenostomy or gastro-jejunostomy, respectively) under EUS and fluoroscopic guidance, with subsequent placement of a LAMS, thus creating a tight and sealed anastomosis, owing to the lumen-to-lumen apposition effect of the stent. The first EUS-GE with LAMS (AXIOS^TM^ stent; Boston Scientific, Marlborough, MA, United States) was described in 2012 in a porcine model by Binmoeller and Shah\[[@B72]\]. In the subsequent years, three different techniques have been described to perform EUS-GE with LAMS: (1) Direct EUS-GE; (2) Assisted EUS-GE, performed using accessory devices (*e.g*., dilating balloon, single balloon overtube, nasobiliary drain, ultra-slim endoscope) for small bowel loop distension before punction and stent placement; and (3) EUS-guided double balloon-occluded gastrojejunostomy bypass (EPASS)\[[@B70],[@B73]-[@B75]\].

Direct EUS-GE requires as first step the puncture of the small bowel loop from the stomach with a 19 Gauge fine needle aspiration (FNA) needle under EUS view. Once confirmed the positioning of the FNA needle into the small bowel through contrast injection under fluoroscopic view, a guide-wire is advanced through the needle into the small bowel, and dilation of the tract with a balloon or a cystotome is performed, to allow the insertion of the stent delivery system (10.8 French) into the small bowel and to open the LAMS. The main technical issues of this technique concern the correct puncturing of the small bowel loop, which is often collapsed and mobile, and the multi-step technique, with several subsequent device exchanges that increase the risk of pushing away the bowel loop with the guide-wire with possible subsequent leakage, perforation or stent mal-deployment. To address these limitations, injection of normal saline (usually about 500 mL) through the duodenal stricture and administering anti-peristaltic drug (*e.g*. glucagone) could help to reduce peristalsis and to have a good view of the target bowel loop. Moreover, LAMS delivery system has further evolved with the addition of an electrocautery tip \[electrocautery-enhanced (EC)-LAMS-HOT-AXIOS^TM^, Boston Scientific Corp., Marlborough, Massachusetts, United States\] which allows a single-stage access to the small bowel distal to the obstruction, without the need of multiple exchanges\[[@B67],[@B76]-[@B78]\].

As resumed above, the assisted EUS-GE technique requires the distension of the jejunal loops distal to the strictures with infusion of normal saline directly injected through an ultra-slim endoscope which is advanced (when possible) beyond the stenosis or passing a nasobiliary catheter over a wire. Alternatively, a balloon is passed over a wire into the jejunum and then inflated, providing a guide for the EUS view to identify the target bowel loop (Figure [5](#F5){ref-type="fig"}). The main limitation of this technique is related to the difficulties in advancing per-orally the mentioned devices through an often tight and angulated duodenal stricture.

![Endoscopic ultrasound view of the distended jejunal loop.](WJG-26-1847-g005){#F5}

The EPASS technique requires a special double-balloon enteric tube (Tokyo Medical University type; Create Medic Co., Ltd, Yokohama, Japan) specifically designed for this procedure\[[@B79],[@B80]\]. The double-balloon tube is inserted perorally over a previously placed guidewire and advanced through the stenosis. Then, both balloons are filled with saline to hold the small intestine open and fixed, and saline with contrast material is introduced into the space between the two balloons to distend the small bowel lumen (Figure [6](#F6){ref-type="fig"}). At this point, the echoendoscope is introduced into the stomach and the distended duodenum or jejunum is identified at the EUS image. The subsequent LAMS placement can be performed with the multi-step procedure described above, or with a single-step procedure using the EC-LAMS.

![Endoscopic ultrasound-guided gastroenterostomy with the double balloon occluder. A: The double balloon occluder in place distending the small bowel in between; B: Endoscopic ultrasound-guided placement of lumen-apposing metal stent between the stomach and jejunum; C: Final endoscopic appearance of lumen-apposing metal stent.](WJG-26-1847-g006){#F6}

Regardless of the technique adopted, data from several studies reported high technical and clinical success rate for EUS-GE in MGOO using 10 mm o 15 mm diameter LAMS, ranging from 87%-96% and 81%-92% respectively\[[@B81]\]. In 2015, Khashab et al\[[@B70]\] and colleagues reported the first series of EUS-GE in both malignant (3 patients) and benign (7 patients) gastric outlet obstruction using the direct or the balloon-assisted technique\[[@B70]\]. The authors reported a technical success of 90% and clinical success of 100%, with resumption of soft or normal diet in all patients with technical success. Moreover, no AEs were reported and patients did not experienced symptom recurrence during a mean follow-up period of 150 d\[[@B70]\]. Itoi et al\[[@B82]\] reported similar outcomes in a prospective study of 20 EUS-GE performed with the EPASS technique, with a technical success of 90% and a significant improvement of GOOSS. Despite a 10% (2 patients) with stent mal-positioning, no further AEs were reported and no patients reported stent migration or occlusion needing re-interventions\[[@B82]\]. Other series reported a rate of AEs ranging from 0 to 21%, including pneumoperitoneum, gastric leak, bleeding, peritonitis or abdominal pain\[[@B74],[@B80],[@B83]-[@B85]\]. A multicenter study comparing the direct and the balloon-assisted technique reported no significant differences in technical and clinical success and AE rate\[[@B86]\]. EUS-GE has been compared to enteral stenting in two retrospective studies\[[@B80],[@B85]\]. Technical success, length of hospitalization and safety were similar, while in the study from Ge e*t al*\[[@B85]\] a higher rate of initial clinical success was found in the EUS-GE group (95.8% *vs* 76.3%, *P* = 0.042)\[[@B85]\]. Strikingly, stent failure requiring re-intervention was significantly lower in EUS-GE group compared to enteral stent group in both studies. A multicenter retrospective study compared EUS-GE (30 patients) and surgical GJ (63 patients)\[[@B83]\]. Despite surgical GJ showed a higher technical success (100% *vs* 87%, *P* = 0.009), clinical success and symptoms recurrence were similar, even if a trend toward more frequent recurrent obstruction in the EUS-GE group (3% *vs* 14%, *P* = 0.08) was reported. A non-significant higher rate of AE rate was found in surgical GJ group (16% *vs* 25 %, *P* = 0.3), however it should be noted that surgery group underwent open GJ, and therefore these results may be not generalizable to laparoscopic GJ\[[@B83]\] (Table [2](#T2){ref-type="table"}).

###### 

Characteristics of the studies comparing endoscopic ultrasound-guided gastroenterostomy with surgical gastrojejunostomy or duodenal stenting in gastric outlet obstruction

  **Ref**.                              **Study characteristics**      **EUS-GE technique**              **Comparison group**    **Number of patients**                       **Technical success**   **Clinical success**   **Hospital stay (d, median)**   **Symptom recurrence or re-intervention**   **Adverse events**
  ------------------------------------- ------------------------------ --------------------------------- ----------------------- -------------------------------------------- ----------------------- ---------------------- ------------------------------- ------------------------------------------- --------------------
  Chen et al\[[@B80]\], 2017            Multicenter; Retrospective     EPASS; Balloon-assisted; Direct   Duodenal SEMS           EUS-GE: 30;                                  26/30 (86.7%);          25/30 (83.3%);         11.3 ± 6.6;                     1/30 (4.3%);                                5/30 (16.7%);
  SEMS: 52                              49/52 (94.2%)                  35/52 (67.3%)                     9.5 ± 8.3               10/52 (28.6%)                                6/52 (11.5%)                                                                                                               
  Khashab et al\[[@B83]\], 2017         Multicenter; Retrospective     EPASS; Balloon-assisted; Direct   Open GJ                 EUS-GE: 30;                                  26/30 (87%);            26/30 (87%);           11.6 ± 6.6;                     1/30 (3%);                                  5/30 (16.7%);
  Open GJ: 63                           63/63 (100%)                   57/63 (90%)                       12 ± 8.2                9/63 (14%)                                   16/63 (25%)                                                                                                                
  Perez-Miranda et al\[[@B84]\], 2017   Multicenter; Retrospective     Assisted; Direct                  Laparoscopic GJ (LGJ)   EUS-GE: 25[1](#T2FN1){ref-type="table-fn"}   23/25 (88%);            21/25 (90%);           9.4;                            NA;                                         3/25 (12%);
  LGJ: 29                               29/29 (100%)                   28/29 (90%)                       8.9                     NA                                           12/29 (41%)                                                                                                                
  Ge et al\[[@B85]\], 2019              Single-center; Retrospective   Assisted; Direct                  Duodenal SEMS           EUS-GE: 22; SEMS: 78                         22/22 (100%);           21/22 (95.5%);         7.4 ± 9.1;                      2/22 (8.3%);                                5/22 (20.8%);
  78/78 (100%)                          60/78 (76.3%)                  7.9 ± 8.2                         31/78 (32%)             39/78 (40.2%)                                                                                                                                                           

Eight patients out of 25 (8/25) underwent endoscopic ultrasonography-guided gastroenterostomy for benign obstruction. EUS-GE: Endoscopic ultrasonography-guided gastroenterostomy; EPASS: Endoscopic ultrasonography-guided double balloon-occluded gastrojejunostomy bypass; SEMS: Self-expanding metal stent; GJ: Gastrojejunostomy.

Taken together, these data propose EUS-GE as a valuable minimal invasive option for patient with MGOO (Figure [7](#F7){ref-type="fig"}). The main limitations concern the technical difficulty of the procedure, which is not yet standardized and requires high skilled therapeutic endoscopists. Moreover, high quality prospective studies comparing the three different palliative strategies are still lacking.

![Computed tomography scan appearance of endoscopic ultrasound-guided gastroenterostomy with lumen-apposing metal stent placed between the stomach and jejunum.](WJG-26-1847-g007){#F7}

CONCLUSION
==========

Palliation of MGOO may be challenging, and multi-disciplinary team is often needed to evaluate the best therapeutic strategy taking into account the patient's performance status, life expectancy, the need of chemo-radiotherapy, surgical risks and, importantly, the patient's preference. In this scenario, the therapeutic endoscopist may offer effective minimal invasive approaches. Enteral stenting provides rapid relief of obstructive symptoms and a short hospital stays through a relatively safe endoscopic procedure compared to surgical GJ. On the other hand, SEMS suffer from high rate of stent failure and need of re-intervention on long-term period, mainly secondary to stent ingrowth, and, for this reason, are the first-line strategy in ill patients with short life expectancy (\< 3 mo). The recently proposed EUS-GE has the ambition to provide a minimal invasive endoscopic procedure, with the consequent safe and rapid efficacy, and, at the same time, with the long-lasting advantages of GJ, as the metal stent is placed away from the neoplastic stricture and therefore is virtually free from ingrowth risk. Despite these exciting novelties, EUS-GE is still a difficult and not standardized technique, and is currently limited to centers with high experience in therapeutic EUS. In the next years, conducting well-designed prospective studies will be the intriguing challenge to identify the best therapeutic option to treat patients with MGOO.
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